Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum
Equillium, Inc., a biotechnology company focused on therapies for autoimmune and inflammatory disorders, announced its management team's participation in a fireside chat at Stifel's 2026 Virtual Immunology and Inflammation Forum. The event will provide investor engagement opportunities and a live webcast of the discussion.